

Dean Engelhardt et al.

Serial No.: Not Yet Assigned

Filed: Herewith

Page 12 (Preliminary Amendment Accompanying Request for a  
Continuation Application Under 37 C.F.R. §1.60 - June 7, 1995)

### **REMARKS**

Applicants are presenting new claims 204-233 in this continuation application under Rule 1.60. It is respectfully that none of the claims herein constitutes the insertion of new matter into the original disclosure.

In the specification above, Applicants have corrected a number of errors of a typographical and/or grammatical nature for the sake of accuracy and completeness.

Applicants have also amended the specification in several instances above by inserting the acronyms, "PM," "SM," and "BASE," for the phosphate, sugar and base moieties, respectively. The insertion of these acronyms has been made in order to conform the terminology in this application with that in other related applications in the patent family. Furthermore, the change in acronyms was originally made in response to non-art rejections in other related applications, and were effected, therefore, to meet the requirements or adopt the suggestions of other patent examiner(s) handling other related applications. It is respectfully submitted that the inclusion of such acronyms into the instant disclosure does not in any way represent the insertion of new matter into the original disclosure. Applicants wish to point out that the designation of the phosphate, sugar and base moieties in the instant claims and specification, are but mere acronyms for the originally disclosed and aforementioned elements. More specifically, these acronyms are logically derived from the elements they represent. For example, "PM" merely connotes the "phosphate moiety;" "SM" the "sugar moiety;" and "BASE" the "base" moiety. The latter is clearly defined or represented in the instant claims as "a pyrimidine, purine or 7-deazapurine moiety," i.e., a base moiety.

Applicants have also deleted the portion of the specification beginning on page 4, line 1, through page 52, line 18. That portion constituted almost the entire contents of Ward et al., U.S. Patent No. 4,711,955, which had not yet issued on June 23, 1982, the original filing date of Serial No. 06/391,440, the seminal application in the family. In order to improve the readability of the specification, therefore, Applicants have hereinabove deleted the bulk of the Ward et

Dean Engelhardt et al.

Serial No.: Not Yet Assigned

Filed: Herewith


Page 13 (Preliminary Amendment Accompanying Request for a  
Continuation Application Under 37 C.F.R. §1.60 - June 7, 1995)

al. disclosure from the specification at hand, while at the same time, maintaining the original language that incorporated by reference the disclosure and the publications cited therein.

The fee for the newly added claims, 204-233 is \$220, based upon an excess number of ten (10) claims presented above the twenty (20) claims already paid or authorized with the continuation request. The Patent and Trademark Office is hereby authorized to charge the amount of \$220 to Deposit Account No. 05-1135. The Patent and Trademark Office is further authorized hereby to charge Deposit Account No. 05-1135 for any other fees due in connection with this Preliminary Amendment or the Request for a Continuation Application, and to credit any overpayment thereto.

Early and favorable action on the claims presented herein is courteously solicited.

Respectfully submitted,



Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants

ENZO DIAGNOSTICS, INC.  
c/o Enzo Biochem, Inc.  
575 Fifth Avenue (18th Floor)  
New York, New York 10017  
(212) 856-0876